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cense.Abstract Tumor hypoxia has been described to increase the resistance of cancer cells to radiation
therapy and chemotherapy. Hypoxia-inducible factor-1a (HIF-1a) is the main transcriptional factor
activated by hypoxia and it plays a key role in reprogramming tumor growth. We examined in this
study whether cobalt chloride induce HIF-1a in different concentrations. U251 human glioblas-
toma cell line was incubated at 16 h under normoxia with or without CoCl2 at 1, 5, 10, 20, 25,
50, 100, 150 and 200 lM treatments. In proliferation assay, CoCl2 have shown an increase in cel-
lular induction between 50 and 200 lM, proportionally. CoCl2 have also shown at 50 lM the max-
imum induction effect. In addition, CoCl2 at 50 lM displayed maximum response at 20,000, 30,000
and 40,000 U251 cells, respectively. In HIF-1 expression assay, CoCl2 increases HIF-1a gene
expression between 50 and 200 lM. Western analysis revealed sharp protein band at 118 KDa
which represented the HIF-1a protein with high band density at 50 lM CoCl2. The present paper
reports the adaptive response of human glioblastoma cells to CoCl2, a chemical hypoxia-mimicking
agent. The effects of the treatment were evaluated on cell proliferation, and HIF-1a gene expres-
sion.
ª 2010 King Saud University. Open access under CC BY-NC-ND license.ity.
lsevier1. Introduction
HIF is a heterodimeric protein that consists of a constitutively
nuclear-located b-subunit, also termed aryl hydrocarbon nu-
clear translocator (ARNT) and a highly regulated a-subunit
(Wang et al., 1995; Jaakkola et al., 2001). Both, a- and b-sub-
units belong to the family of proteins that contain basic helix-
loop-helix (bHLH) and PER-ARNT-SIM (PAS) motifs that
are crucial for heterodimerisation between the HIF-a and
HIF-b subunits (Wang et al., 1995). To date, three HIF-a sub-
units with speciﬁc tissue expression patterns have been identi-
ﬁed (HIF-1a, HIF-2a, and HIF-3a) (Hogenesch et al., 1997).
198 M.S. Al OkailHIF-1a contains oxygen-dependent degradation domain
(ODDD) that is central to the oxygen-regulated stability of
this protein (Pugh et al., 1997). HIF-1a also contains in its
C-terminal region two transactivation domains, N-terminal
(N-TAD), and C-terminal (C-TAD), respectively (Ruas
et al., 2002). These transactivation domains mediate interac-
tion of the HIF transcription factor with other co-activators
of gene transcription, such as p300/CBP, that confer target
gene speciﬁcity (Lando et al., 2002; Hu et al., 2007).
In a normoxic condition, HIF-1a is hydroxylated on spe-
ciﬁc proline or asparagine residues by enzymes that have an
absolute requirement for dioxygen (O2), Fe (II) and 2-oxoglu-
tarate (McNeil et al., 2002). Four hydroxylases have been de-
scribed to act on HIF-1a: (i) three prolyl-4-hydroxylase
domain-containing enzymes (PHD1-3), which modify the pro-
line residues Pro402 and Pro564 and (ii) FIH (factor inhibiting
HIF) which modiﬁes an asparagine residue Asn803 (Walmsley
et al., 2008) (Fig. 1). Both, Pro402 and Pro564 are located in
the ODDD, while Asn803 is located in the C-TAD of HIF-
1a. This novel group of hydroxylase enzymes (PHDs and
FIH) show an absolute necessity for dioxygen, Fe (II) and 2-
oxoglutarate. The proteosomal degradation of HIF is depen-
dent on the targeting of prolyl hydroxylated a-subunits to
the ubiquitin pathway by high-afﬁnity binding to the von
Hippel Lindau E3 ubiquitin ligase (VHL) (Jaakkola et al.,
2001). Thus, reduced PHD and FIH hydroxylase activity at
oxygen tension site permits stabilization and transcriptional
activation of HIF resulting in the modulation of multiple
HIF effector genes which contain hypoxia response elements
(HRE), to facilitate the cellular adaptive responses to hypoxia
(Wenger, 2002).
Furthermore, HIF-1a plays a central role in tumor progres-
sion and angiogenesis in vivo. Oncogenic activation or loss of
tumor suppressor function is associated with HIF-1-mediated
tumor progression (Ba´rdos et al., 2004). Exposure to a variety
of growth factors has also been shown to increase HIF-1a
activity in normoxic and hypoxic conditions. HIF-1a is overex-
pressed in many human cancers and has been associated with
tumor aggressiveness, vascularity, treatment failure and mor-
tality (Birner et al., 2000; Giaccia et al., 2003). All of these
activities make the HIF-1a transcription factor an attractive
target for the development of new anticancer therapeutics
(Belozerov and Meir, 2005).Prolyl  
Hydroxylase
O2,Fe2+,2-oxoglutarate 
Figure 1 Under normal oxygen tensions, HIF-1a is hydroxyl-
ated by prolyl hydroxylases, which require oxygen, ferrous ion,
and 2-oxoglutarate for activity. Prolyl-4-hydroxylases (PHD1-3)
modify the proline residues Pro402 and Pro564.Some metals are known as hypoxic mimicking agents
including cobalt chloride, nickel chloride and desferrioxamine
(Goldberg et al., 1998). Epstein et al. (2001) reported that spe-
ciﬁc prolyl hydroxylases have an iron-binding centre and that
iron is critical for their enzymatic activities. It is proposed that
iron chelators can remove iron from the iron-binding centre of
the enzyme and that the iron can be replaced with cobalt at this
site, which will inactivate the hydroxylation activity. It was
also reported that CoCl2 treatment induced HIF-1a expression
by binding to the PAS domain resulting in blockage of HIF-1a
pVHL binding and thereby HIF-1a stability (Yuan et al.,
2003).
The purpose of this study is to investigate the role of CoCl2
in U251 human glioblastoma cell proliferation and to deter-
mine potential interactions between CoCl2 and HIF-1a in
these cells in normoxia conditions. Therefore, we applied dif-
ferent CoCl2 concentrations to investigate the cellular induc-
tion, as well as the effect of CoCl2 in U251 cell density, and
studied the effects of CoCl2 on HIF-1a gene expression at pro-
tein levels, in U251 human glioblastoma cells.2. Materials and methods
2.1. Cell line and reagents
U251 human glioma cell line obtained from ECCAC (UK) and
maintained in RPMI 1640 (Whittacker Bioproducts, Walkers-
ville, USA) supplemented with 5% heat-inactivated fetal bo-
vine serum (Imperial Laboratories, Andover, UK), penicillin
(50 IU/ml), streptomycin (50 lg/ml) and 2 mM glutamine (all
purchased from Sigma, UK). Cells were maintained at 37 C
in a humidiﬁed incubator containing 21% O2, 5% CO2 in air
(referred to as normoxic conditions).
2.2. Hypoxic treatment
To prepare CoCl2 stock solutions in RPMI 1640 tissue culture
medium, usually as 10% w/v solutions, the chemicals were dis-
solved directly in culture medium (800 lM/10 ml RPMI). The
stock solutions were ﬁlter-sterilized (0.22 lm). The resultant
solutions were kept at 4 C and used within 24 h for the assay.
Nine separate serial CoCl2 (Sigma, UK) concentrations in cul-
ture medium were prepared for addition to cell culture (1, 5,
10, 20, 25, 50, 100, 150 and 200 lM).
U251 cell culture medium was removed from the ﬂask and
the cells were rinsed with Trypsin EDTA solution and Trypsin
EDTA solution (sigma) were then added to the ﬂask and incu-
bated at 37 C for 2 min. Cells were then resuspended with
RPMI 1640 and cultured at a concentration of 5000 cells/well
in tissue culture 96 wells plates. The cells were left 48 h to ad-
here at 37 C in a humidiﬁed atmosphere tissue culture incuba-
tor containing 5% CO2. After 48 h, cells were treated with
serial CoCl2 concentrations (1, 5, 10, 20, 25, 50, 100, 150 and
200 lM) with 20% O2 at 37 C for 16 h.
2.3. Cell density experiment
U251 cell suspensions were prepared in a standard manner.
Culture medium was removed from the ﬂask and the cells were
rinsed with Trypsin EDTA solution and Trypsin EDTA solu-
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37 C for 2 min. In order to monitor the cellular sensitivity
of CoCl2, U251 suspensions were seeded in a standard manner
at 5000, 10,000, 15,000, 20,000, 30,000 or 40,000 cells per
75 cm2 tissue culture ﬂasks.
2.4. Cell proliferation assay
The U251 human cell line were grown and treated with CoCl2
as mentioned above. The Promega CellTiter 96 AQueous
non-radioactive cell proliferation assay has been applied here
for in vitro cytotoxicity assessment. This assay uses the novel
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carb-
oxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt; MTS) and the electron coupling reagent, phenazine
methosulfate (PMS). MTS is chemically reduced by cells into
formazan, which is soluble in tissue culture medium (Malich
et al., 1997). The measurement of the absorbance of the forma-
zan can be carried out using 96 microplates at 492 nm. The as-
say measures dehydrogenase enzyme activity found in
metabolically active cells. Since the production of formazan
is proportional to the number of living cells, the intensity of
the produced color is a good indication of the viability of
the cells. MTS solutions were prepared according to the man-
ufacturer’s instructions. The solutions were then stored in
light-protected tubes at 20 C.
A sample of culture medium was used as a ‘‘medium-only’’
control. The same cell suspension as that prepared for the as-
say was also used as a ‘‘cell-only’’ control as untreated. Prome-
ga CellTiter 96 AQueous. The ﬁnal solutions were added, in
duplicates (100 ll in each well) using a multichannel pipettor,
then one solution reagent was added directly at 10 ll to culture
wells then the 96 microwell plates were returned to the tissue
culture incubator for 1–4 h/37 C to allow the colorimetric
reaction to occur then measured at 490 nm. The microplate
was incubated for another 4 h under identical conditions.
2.5. Nuclear extract preparation
Nuclear extracts were prepared from U251 cells as described
(Jiang et al., 1996). We routinely collected the U251 cells after0
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Figure 2 Cobalt chloride dose response concentration in cell prolifera
10, 20, 25, 50, 100, 150 and 200 lM) at 37 C under 20% O2 for 16
three independent experiments.72 h in which they usually reached 70% conﬂuent then cells
washed twice with ice-cold Dulbecco’s PBS 1· (PBS) and pel-
leted by centrifugation at 1200 rpm at 4 C. The cell pellet was
subsequently washed once in a hypotonic buffer (10 mM Tris–
HCl (pH 7.5), 1.5 mMMgCl2, 10 mMKCl, 2 mMDTT, 1 mM
Pefabloc, 2 mM sodium vanadate, 4 lg/ml pepstatin, 4 lg/ml
leupeptin, and 4 lg/ml aprotinin), resuspended in the same
buffer, and incubated for 10 min on ice. The cell suspension
was homogenized with 18–20 strokes in a glass Dounce
homogenizer. The nuclear pellet was obtained after centrifuga-
tion at 1000g at 4 C for 10 min and resuspended in a hyper-
tonic buffer (20 mM Tris–HCl (pH 7.5), 1.5 mM MgCl2,
0.42 M KCl, 20% glycerol, 2 mM DTT, 1 mM Pefabloc,
2 mM sodium vanadate, 4 lg/ml pepstatin, 4 lg/ml leupeptin,
and 4 lg/ml aprotinin) to obtain nuclear extracts. The nuclear
suspension was rotated at 4 C for 30 min, and nuclear debris
were pelleted by centrifugation at 15,000 g for 30 min at 4 C.
The protein concentration was determined and standardized
using the Bradford protein assay (Bradford, 1976) with bovine
serum albumin (Sigma, UK) as the standard.
2.6. SDS–PAGE and Western blot analysis
Extracts of U251 cell line were processed for Western blot
according to previously published methods (Alokail, 2005).
Twenty micrograms of protein was resolved by electrophoresis
on 12% polyacrylamide gels and electrotransferred on an
Immobilon-P membrane. After blocking with 5% non-fat
dry milk in PBS() containing 0.01% Tween-20 (T-PBS), the
membrane was blotted overnight at 4 C in rotation with pri-
mary anti-HIF-1a monoclonal antibody (diluted 1:400 in
blocking buffer) (Santa Cruz Biotechnology, USA). The blots
were then washed in T-PBS (1· PBS and 0.1% Tween-20)
three times for 5 min each time at room temperature with rota-
tion. Membranes were incubated for 2 h at room temperature
with a horseradish peroxidase-conjugated secondary anti-
mouse Ig monoclonal antibody (diluted 1:2000 in blocking
buffer) (Santa Cruz Biotechnology, USA). Membranes were
then washed three times in T-PBS buffer, and chemilumines-
cence detection was performed using an enhanced chemilumi-
nescence kit according to the manufacturer’s protocol (ECL25
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tion. U251 cells were treated with serial CoCl2 concentrations (1, 5,
h as mentioned in Section 2. Results represent means ± SE of
200 M.S. Al OkailWestern blotting analysis system, Amersham Pharmacia Bio-
tech, Buckinghamshire, UK). HIF-1a protein band signals
were detected by Bio-Rad Imager system (Bio-Rad, UK).
3. Results
In order to reach maximum HIF-1a stimulation, different
working CoCl2 concentrations (1, 5, 10, 20, 25, 50, 100, 150
and 200 lM) were prepared and applied as ﬁnal CoCl2 treat-
ment in U251 cell culture. In CoCl2 concentrations under
20% O2 at 37 C for 16 h, the cell proliferation assay have
shown that the CoCl2 treatment for 16 h induced the U251
cells in a dose-dependent manner until 50 lM (Fig. 2) then de-
creased and become steady between 100 and 200 lM. The
treatment duration was deduced from several pre-experiments
(data not shown) to maximize the effect of CoCl2 on the U251
cell line and minimize the possible confounding effects of
CoCl2 itself on the cell culture.
In order to determine the cellular density of U251 cell cul-
ture and the effect of 50 lM CoCl2 sensitivity, U251 suspen-
sions were prepared in a standard manner (5000, 10,000,
15,000, 20,000, 30,000 and 40,000) cells were grown inFigure 3 Effect of cobalt chloride in cellular proliferation. The
U251 human cell line were seeded at 5000, 10,000, 15,000, 20,000,
30,000 or 40,000 cells per 75 cm2 tissue culture ﬂasks then all cells
were treated for 16 h with CoCl2 (50 lM) as mentioned in Section
2. Results represent means ± SE of three independent
experiments.
             100    Untreated             50              200 µM CoCl2
HIF-1 
(118 KDa)
Figure 4 Induction of HIF-1a protein expression by cobalt
chloride. Effect of PEITC on proteasome inhibitor-induced HIF-
1a activity. U251 human cells were left untreated, or treated with
50,100, or 200 lM CoCl2 for 1 h. Expression of HIF-1a deter-
mined by Western blot analysis. HIF-1a band detected 118 kDa.
Results represent one of three independent experiments.75 cm2 tissue culture ﬂasks as mentioned in Section 2. The data
have shown that 50 lM CoCl2 have shown a maximum stimu-
lation in a high cell density (30,000 and 40,000 cells/well) com-
pared with weak response in low cell density (5000, 10,000,
15,000 and 20,000), (Fig. 3).
Moreover, in HIF-1a gene expression, CoCl2 treatment for
16 h induced the expression of HIF-1a in a dose-dependent
manner until 200 lM (Fig. 4). Again, 50 lM CoCl2 have
shown a higher HIF-1a expression compared with other con-
centrations. The HIF-1a protein expression have also reveled
in Western blot analysis one sharp protein band at 118 kilo
Dalton which represented the HIF-1a band.4. Discussion
When the tumor grows, it develops extensive regions of poor
oxygenation and high acidity due to the discrepancy between
the rapid rate of tumor growth and the capacity of existing
blood vessels to supply oxygen (Hockel and Vaupel, 2001).
At a cellular level, a hypoxic stress generates an adaptive re-
sponse that is mediated by the HIF-1a (Semenza, 1998). Thus
a positive correlation between HIF-1a over expression and
poor prognosis has been reported (Sohda et al., 2004; Theod-
oropoulos et al., 2004).
HIF-1a induces synthesis of proteins that promote meta-
bolic changes in the cells of hypoxic tissues and, induces neo-
vascularization to re-establish an adequate oxygen supply.
Consequently, cells and tissues adapt to a broad range of oxy-
gen concentrations, from normoxia (21% O2) to hypoxia
(1–5% O2) Wang et al., 1995. HIF-1a is central to regulation
of apoptosis and cell survival, cell adhesion and extracellular
matrix turnover, cytoskeletal structure, cell motility, epithelial
homeostasis, vascular tonus, erythropoiesis and iron metabo-
lism, metabolic homeostasis, and pH regulation (Brahimi-
Horn et al., 2005).
In mammalian systems, CoCl2 has been used as a chemical
agent that reportedly induces a biochemical and molecular re-
sponse similar to that observed under low-oxygen conditions
(Grasselli et al., 2005). Many reports have shown that both co-
balt and hypoxia regulate a similar group of genes on a global
gene expression level (Lee et al., 2001; Vengellur et al., 2003).
In addition to this, CoCl2 has been widely used as a hypoxia-
mimicking agent in both in vivo (Badr et al., 1999) and in vitro
studies (Wang and Semenza, 1993). Cobalt is essential for hu-
man health because of its critical role in the synthesis of vita-
min B12 (Roessner et al., 2001), however, excess exposure of
cobalt can lead to tissue and cellular toxicity.
In this study, we investigate the effects of the hypoxia-mi-
metic CoCl2 in U251 human glioblastoma cells. We demon-
strate that CoCl2 treatment leads to increase HIF-1a gene
expression and cellular induction of these cells. In comparison
with previous experiments on gene expression (Chang et al.,
2007), found limited similarity in the transcriptional response
to CoCl2, demonstrating that these treatments have distinct ef-
fects on cell physiology. We therefore propose that in U251
human glioblastoma cells the response to CoCl2 mimics certain
aspects of normoxia by targeting HIF-1a gene and various
proteins that promote metabolic changes in the cells. Due to
this, CoCl2 appears to be an effective chemical to screen for
all pathways involved in oxygen sensing, and may be useful
in HIF-1a as central in regulation of apoptosis and cell sur-
Cobalt chloride, a chemical inducer of hypoxia-inducible factor-1a in U251 human glioblastoma cell line 201vival. Other group, however, suggested that CoCl2 appears to
be not an effective in pathways involved in oxygen sensing, but
may be useful in uncovering factors involved in the Sre1p-med-
iated response (Lee et al., 2007).
As for all proteins, the balance between the rate of synthesis
and the rate of catabolism determines the HIF-1a protein level.
While HIF-1a protein synthesis is regulated by O2-indepen-
dent mechanisms, HIF-1a protein degradation is primarily
regulated through O2-dependent mechanisms. Under normox-
ic conditions the catabolic rate of the a-subunit is very high
and thus the protein is generally not undetectable, while under
hypoxic conditions the a-subunit is stable and available for
binding to the b-subunit to form an active transcriptional het-
erodimer. In addition, both O2-independent and O2-dependent
mechanisms mediate posttranslational modiﬁcations that alter
protein stability and transcriptional activity. Furthermore, the
expression of HIF-1a protein is modulated through different
pathways that alter HIF-1-dependent transcriptional activity
and makes the HIF-1a transcription factor an attractive target
for new drug development. For example, a number of antican-
cer drugs have been shown to inhibit HIF-1a, but none of
these drugs target HIF-1a directly and speciﬁcally (Semenza,
2003; Generali et al., 2006; Powis and Kirkpatrick, 2004).
However, most inhibitors affect multiple signaling pathways
and only indirectly target the HIF-1a transcription factor.
Therefore, the ability to identify, visualize and validate
changes in the dynamics and stability of the HIF-1a protein
is likely to be useful as a pharmacodynamic end point and
read-out of inhibition in the development of new anticancer
drugs that target HIF-1a in the future.
The present paper reports the adaptive response of U251
human glioblastoma cells to cobalt chloride CoCl2, a chemical
hypoxia-mimicking agent. The effects of the treatment were
evaluated on cell proliferation and HIF-1a gene expression.
In addition, because HIF-1a plays a central role in tumor pro-
gression, angiogenesis in vivo and oncogenic activation or loss
of tumor suppressor function is associated with HIF-1a med-
iated tumor progression, HIF-1a gene expression levels were
investigated. In the present study, CoCl2 had U251 cellular
induction and stimulated HIF-1a gene expression. Thus, we
suggested here the more experiments are needed to deﬁne
HIF-1a since we are interested in brain cancer and its cell
death-related mechanisms.References
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